24 July 2018
Visiongain’ has launched a new pharma report Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs
Ophthalmic pharmaceuticals are pharmaceutical agents used to treat eye diseases, such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, ocular allergies, infections, inflammatory conditions and dry eye. A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas.
The lead analyst of the report commented “For many indications, the advantages of pharmaceutical treatment far outweigh the benefits offered by alternative treatments such as surgery. As glaucoma, retinal disorders, inflammatory conditions and moderate to severe dry eye require management by medical professionals, the preferred treatment will be largely guided by clinical considerations rather than competition between alternative treatments.
Gene therapies and other regenerative medicine approaches to ophthalmic diseases may become effective substitutes towards the end of the forecast period. The area of gene therapy is still in its infancy with only a handful of currently marketed products. There is much research interest in gene therapies for conditions such as Leber’s congenital amaurosis and retinitis pigmentosa.”
Leading companies featured in the report include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market